ReneuRx™ Therapy
Knee Pain (Orthopedic Pain)
Phase 1Active
Key Facts
About Brixton Biosciences
Brixton Biosciences is pioneering a novel approach to pain management with its ReneuRx™ therapy, a nerve-selective treatment intended to deliver months of pain relief from one injection. The company, founded by clinicians and researchers from Massachusetts General Hospital and Harvard Medical School, initiated its first-in-human clinical trial in 2023 for knee pain. Brixton aims to address the massive unmet need in pain control, potentially reducing reliance on short-acting anesthetics and opioids, which carry significant risks of addiction and abuse. Its initial focus is the orthopedic pain market, with a long-term vision to treat a broader spectrum of pain conditions.
View full company profile